Business Standard

Wednesday, December 25, 2024 | 03:52 PM ISTEN Hindi

Notification Icon
userprofile IconSearch

Kopran hits 52-week high after Crisil upgrades rating outlook to 'Positive'

The rating agency reaffirmed its 'CRISIL BBB' rating on long term bank facilities, while short term ratings has been reaffirmed at 'CRISIL A3+'

The government is now trying to understand how long it will take before the drug’s production can start in India
Premium

The government is now trying to understand how long it will take before the drug’s production can start in India

SI Reporter Mumbai
Shares of Kopran were locked in the 5 per cent upper circuit band at Rs 97.35 on the BSE on Tuesday, gaining 10 per cent in the past four trading days, after rating agency Crisil revised its outlook on the long term bank facilities of the company to 'Positive' from 'Stable'. The rating agency reaffirmed its 'CRISIL BBB' rating on long term bank facilities, while short term ratings has been reaffirmed at 'CRISIL A3+'.

The stock of the pharmaceutical company was trading at its 52-week high level. In the past one month, it has rallied 39 per cent as compared to

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in